EC clears Plegridy

|By:, SA News Editor

The European Commission approves Biogen Idec's (BIIB +11.2%) Plegridy (peginterferon beta-1a) as a treatment for adults with relapsing-remitting multiple sclerosis (RRMS). It is the only pegylated interferon approved for RRMS.

Patients dose themselves every two weeks with a subcutaneous injection using a prefilled syringe.

Plegridy is Biogen's fifth product offering for MS.